Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Renal Cell 26Prostatic Neoplasms 5Osteosarcoma 5Neuroendocrine Tumors 5Neoplasms 5Kidney Neoplasms 5Colorectal Neoplasms 5Carcinoma, Hepatocellular 5Neoplasm Metastasis 4Urinary Bladder Neoplasms 3Urethral Neoplasms 3Sarcoma, Ewing 3Sarcoma 3Clear-cell metastatic renal cell carcinoma 3Carcinoma, Transitional Cell 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Medullary 3Urogenital Neoplasms 2Ureteral Neoplasms 2Small Cell Lung Carcinoma 2Penile Neoplasms 2Melanoma 2Lung Neoplasms 2Central Nervous System Neoplasms 2Carcinoma 2Adrenocortical Carcinoma 2von Hippel-Lindau Disease 1Wilms Tumor 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1

Interventions

Educational Status 3Methods 2Interviews as Topic 2Early Intervention, Educational 2veliparib 1pamiparib 1dinaciclib 1cabozantinib 1Specimen Handling 1Pharmacogenomic Variants 1Palliative Care 1Paclitaxel 1Nutrition Assessment 1Health Promotion 1Diet Therapy 1Behavior Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Malignant Solid Neoplasm × cabozantinib × 90 days × Clear all
NCT05038839 2026-05-12

Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors

M.D. Anderson Cancer Center

Phase 1 Completed
44 enrolled
Other solid neoplasm

Advanced Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡